Early-onset Alzheimer’s disease (EOAD), which affects individuals typically between 30 and 60 years old, is a devastating condition marked by progressive memory loss, cognitive decline, and behavioral changes. Despite its severity and the unique challenges it poses, there is growing concern that EOAD cases are not receiving adequate attention from Washington elites, including policymakers and funding bodies. This neglect may stem from a combination of factors such as the rarity of EOAD compared to late-onset Alzheimer’s, misconceptions about who Alzheimer’s affects, and competing political priorities.
EOAD differs from the more common late-onset Alzheimer’s primarily in the age of onset and often in its genetic underpinnings. Mutations in genes such as presenilin 1, presenilin 2, and the amyloid precursor protein (APP) are known to cause familial forms of EOAD, leading to earlier and more aggressive disease progression. Symptoms include unusual memory loss, difficulty with problem-solving, confusion about time and place, language disturbances, mood swings, and withdrawal from social and work activities. As the disease advances, individuals may lose the ability to perform basic tasks and require full-time care. These symptoms can be particularly devastating for people in their prime working years, often with families to support, making the social and economic impact profound.
Despite these challenges, EOAD remains underrecognized in public discourse and policy. One reason is that Alzheimer’s is widely perceived as a disease of the elderly, which can lead to a lack of awareness about younger patients who suffer from it. This misconception affects funding priorities, research focus, and healthcare resources. While late-onset Alzheimer’s affects millions and commands significant attention, EOAD patients—though fewer in number—face unique hurdles such as misdiagnosis, delayed diagnosis, and insufficient support systems tailored to younger adults.
Washington elites, including lawmakers and federal agencies, often prioritize health issues based on prevalence and political visibility. EOAD’s relatively low incidence compared to other diseases means it struggles t
